In vivo manipulation of human breast cancer growth by estrogens and growth hormone: kinetic and clinical results.
Since 1983, a series of experimental and clinical studies have been carried out on the possibility of enhancing the chemotherapy effectiveness in breast cancer by expanding the fraction of cycling cells. Theoretically estrogens should recruit breast cancer cells and this fact should result in a higher killing efficiency of antiproliferative drugs. Actually it has been clearly shown, by means of the thymidine labeling index and primer-dependent alpha-DNA polymerase assay, that low doses of diethylstilbesterol are able to increase the tumor proliferative activity of human breast cancer in vivo (estrogenic recruitment). Three randomized trials have been carried out (one in locally advanced and two in metastatic breast cancer) comparing conventional polychemotherapy vs chemotherapy with estrogenic recruitment. Only limited advantages have been observed in these trials. Searching for new modalities of kinetic manipulation of tumors, recombinant human growth hormone has been employed in a pilot study: the preliminary results indicate that it largely enhances tumor proliferative activity, suggesting the possibility of employing a growth factor system to increase chemosensitivity.
Conte
P F
PF
Istituto Nazionale per la Ricerca sul Cancro, Genova, Italia.
Gardin
G
G
Pronzato
P
P
Miglietta
L
L
Rosso
R
R
Amadori
D
D
Gentilini
P
P
Monzeglio
C
C
Gallotti
P
P
Demicheli
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D002471:Cell Transformation, Neoplastic / Q000187:drug effects*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004967:Estrogens / Q000494:pharmacology*; D005260:Female; D006062:Gonadotropins / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000494:pharmacology*
D004967:Estrogens; D006062:Gonadotropins; D011994:Recombinant Proteins; D013004:Somatostatin; D004054:Diethylstilbestrol; D003520:Cyclophosphamide